Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers.
作者信息
Cui Qingbin, Wang Cong, Zeng Leli, Zhou Qian-Xiong, Fan Ying-Fang
机构信息
Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States.
State Key Laboratory of Esophageal Cancer Prevention and Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
出版信息
Front Chem. 2022 May 4;10:921985. doi: 10.3389/fchem.2022.921985. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers.社论：用于克服癌症多药耐药性的新型小分子药物
Front Chem. 2022 May 4;10:921985. doi: 10.3389/fchem.2022.921985. eCollection 2022.
2
Anticancer and multidrug-resistance reversing potential of traditional medicinal plants and their bioactive compounds in leukemia cell lines.传统药用植物及其生物活性化合物在白血病细胞系中的抗癌及多药耐药逆转潜力
Chin J Nat Med. 2014 Dec;12(12):881-94. doi: 10.1016/S1875-5364(14)60131-X.
3
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.针对多药耐药相关蛋白 1（MRP1）表达的癌症：超越药理抑制。
Drug Resist Updat. 2021 Dec;59:100795. doi: 10.1016/j.drup.2021.100795. Epub 2021 Dec 10.
4
Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.Raf-1/Mdr-1 siRNAs 共转染对 KBv200 细胞系多药耐药性的逆转作用。
Oral Oncol. 2009 Nov;45(11):991-7. doi: 10.1016/j.oraloncology.2009.05.642. Epub 2009 Jul 23.
5
Repurposing old drugs to fight multidrug resistant cancers.将老药重新用于治疗多药耐药性癌症。
Drug Resist Updat. 2020 Sep;52:100713. doi: 10.1016/j.drup.2020.100713. Epub 2020 Jun 25.
6
Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR).一种可调节ABCB1介导的多药耐药性（MDR）的无毒[1,2,4]三唑并[1,5-a]嘧啶-7-酮（WS-10）的发现。
Bioorg Med Chem. 2018 Dec 1;26(22):5974-5985. doi: 10.1016/j.bmc.2018.10.027. Epub 2018 Nov 3.
7
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.重组人干扰素α增强MRK - 16单克隆抗体对多药耐药性的逆转作用。
J Natl Cancer Inst. 1995 Jan 18;87(2):94-104. doi: 10.1093/jnci/87.2.94.
8
Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil.代谢组学分析结直肠癌细胞多药耐药及其维拉帕米逆转多药耐药的作用
Biomed Chromatogr. 2021 Feb;35(2):e4976. doi: 10.1002/bmc.4976. Epub 2020 Sep 28.
9
Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents.发现解决多药耐药性的方法：新型药物的设计、合成与生物评价。
Arch Pharm (Weinheim). 2019 Oct;352(10):e1900127. doi: 10.1002/ardp.201900127. Epub 2019 Aug 23.
10
Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance.发现具有三唑核的芳酰胺类化合物作为逆转 P-糖蛋白介导的多药耐药性的有效抑制剂。
Bioorg Chem. 2019 Sep;90:103083. doi: 10.1016/j.bioorg.2019.103083. Epub 2019 Jun 21.
引用本文的文献
1
Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers.靶向凋亡抑制蛋白（IAPs）以对抗癌症中的耐药性。
Front Pharmacol. 2025 Mar 28;16:1562167. doi: 10.3389/fphar.2025.1562167. eCollection 2025.
2
Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterization.ABCB1的过表达赋予癌细胞对FLT3抑制剂FN-1501的抗性：体外和体内特征研究
Am J Cancer Res. 2023 Dec 15;13(12):6026-6037. eCollection 2023.
3
Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001).安罗替尼联合XELOX方案作为转移性结直肠癌一线治疗的疗效和安全性：一项单臂、多中心、II期研究（ALTER-C-001）
Front Oncol. 2023 Sep 1;13:1238553. doi: 10.3389/fonc.2023.1238553. eCollection 2023.
4
The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.AKT抑制剂MK-2206可减弱ABCG2介导的肺癌和结肠癌细胞耐药性。
Front Pharmacol. 2023 Jul 13;14:1235285. doi: 10.3389/fphar.2023.1235285. eCollection 2023.
5
Biogenic Synthesis of Cu-Mn Bimetallic Nanoparticles Using Pumpkin Seeds Extract and Their Characterization and Anticancer Efficacy.利用南瓜籽提取物生物合成铜锰双金属纳米颗粒及其表征与抗癌功效
Nanomaterials (Basel). 2023 Mar 28;13(7):1201. doi: 10.3390/nano13071201.
6
A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.一项多中心、单臂、Ⅱ期研究，评估安罗替尼联合紫杉醇和顺铂作为复发性/晚期食管鳞癌一线治疗的疗效。
BMC Med. 2022 Dec 8;20(1):472. doi: 10.1186/s12916-022-02649-x.
本文引用的文献
1
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models.一种新型PI3K抑制剂XH30可抑制小鼠模型中的原位胶质母细胞瘤和脑转移。
Acta Pharm Sin B. 2022 Feb;12(2):774-786. doi: 10.1016/j.apsb.2021.05.019. Epub 2021 May 26.
2
Navigating Calcium and Reactive Oxygen Species by Natural Flavones for the Treatment of Heart Failure.天然黄酮类化合物调控钙和活性氧以治疗心力衰竭
Front Pharmacol. 2021 Nov 9;12:718496. doi: 10.3389/fphar.2021.718496. eCollection 2021.
3
Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities.人类恶性肿瘤对免疫疗法的抗性：机制、研究进展、挑战与机遇
J Cell Physiol. 2022 Jan;237(1):346-372. doi: 10.1002/jcp.30575. Epub 2021 Sep 8.
4
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance.多药耐药蛋白（MRPs）：结构、功能与克服肿瘤多药耐药性。
Drug Resist Updat. 2021 Jan;54:100743. doi: 10.1016/j.drup.2021.100743. Epub 2021 Jan 13.
5
Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.沙匹替尼逆转过表达ABCB1转运蛋白的结肠癌细胞中的抗癌药物耐药性。
Front Oncol. 2020 Oct 9;10:574861. doi: 10.3389/fonc.2020.574861. eCollection 2020.
6
Mechanisms of Cancer Resistance to Immunotherapy.癌症对免疫疗法的耐药机制。
Front Oncol. 2020 Aug 6;10:1290. doi: 10.3389/fonc.2020.01290. eCollection 2020.
7
Repurposing old drugs to fight multidrug resistant cancers.将老药重新用于治疗多药耐药性癌症。
Drug Resist Updat. 2020 Sep;52:100713. doi: 10.1016/j.drup.2020.100713. Epub 2020 Jun 25.
8
An overview of drug discovery and development.药物发现与开发概述。
Future Med Chem. 2020 May;12(10):939-947. doi: 10.4155/fmc-2019-0307. Epub 2020 Apr 9.
9
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019.天然产物：1981 年 1 月至 2019 年 9 月近四十年来的新药来源
J Nat Prod. 2020 Mar 27;83(3):770-803. doi: 10.1021/acs.jnatprod.9b01285. Epub 2020 Mar 12.
10
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.通过靶向鞘氨醇激酶-1 克服黑色素瘤对免疫检查点抑制剂的耐药性。
Nat Commun. 2020 Jan 23;11(1):437. doi: 10.1038/s41467-019-14218-7.
Zotero 插件